Company signals · Biotech & Pharma
Flagship Pioneering
1 signal in the current window, with MitchelLake's leadership read on each.
Market context: This lands while the Talent Market Index reads 113.7 (Hot) — up 13.7 versus the prior month — and EMEA signal share is steady (-1.5pts).
Flagship Pioneering: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 23 tracked companies; 0.1% of MitchelLake's EMEA signal flow.
Signals at Flagship Pioneering
More signals across Biotech & Pharma
Partnership · EMEA
UCB →UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Partnership · EMEA
Thermo Fisher Scientific →Thermo Fisher Scientific awarded UK government contract: "Supply of 2 Ion Chromatography systems" — buyer: Nuclear Restoration Services Limited
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim initiated three Phase III clinical trials in precision oncology: two DAREON® programme trials (DAREON®-Lung-1 in SCLC and DAREON®-NEC-1 in epNEC) and Beamion LUNG-3 trial in HER2-mutant NSCLC. This represents advancement of biomarker-informed oncology pipeline.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Product Launch · EMEA
Amgen →European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Ma Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Intelligence powered by Autonodal ↗